Nivolumab: targeting PD-1 to bolster antitumor immunity | Future Oncology
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives - Cancer Treatment Reviews
Pharmacokinetic/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: Part 2, immune checkpoint inhibitor antibodies - ScienceDirect
Small Cell Lung Cancer Transformation as a Mechanism of Resistance to PD-1 Therapy in KRAS-Mutant Lung Adenocarcinoma: A Report of Two Cases - Journal of Thoracic Oncology
How Combination Therapy Works | OPDIVO® (nivolumab) + YERVOY® (ipilimumab)
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations | Journal for ImmunoTherapy of Cancer | Full Text
EPOS™
Nivolumab Mechanism of Action – ACKC.org
How OPDIVO® Works | OPDIVO® (nivolumab)
DoD Award for Enhancing Immune Checkpoint Inhibitors – ACKC.org
Frontiers | First-Line Immune-Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Landscape and Future Progress | Pharmacology
Nivolumab (Opdivo) Drug Information
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy | Nature Reviews Cancer
Immune-based combination therapy for metastatic kidney cancer | Nature Reviews Nephrology
How OPDIVO® Works | OPDIVO® (nivolumab)
Spotlight on New Cancer Immunotherapy: Ono Pharmaceutical's Opdivo | Nippon.com
Cancers | Free Full-Text | Landscape and Future Perspectives of Immunotherapy in Neuroendocrine Neoplasia | HTML
Download nivolumab images for free
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action | Immunotherapy
IJMS | Free Full-Text | Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials | HTML
Immune checkpoint inhibition in gastric cancer: A systematic review - ScienceDirect
